In this podcast based on the ESC 2021 poster, 'Effects of Dapagliflozin in Patients With Chronic Kidney Disease, With and Without Heart Failure', Prof John McMurray (University of Glasgow, UK) provides a comprehensive overview of the study's background, methods and results.
Previous studies have demonstrated that sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of heart failure (HF) hospitalisation in patients with type 2 diabetes, including in those with chronic kidney disease (CKD). This reduced risk is also evident in patients with HF or CKD with or without type 2 diabetes. In the DAPA CKD study, the authors examined the outcomes in patient with CKD with and without type 2 diabetes by history of HF at baseline.
Here, the poster authors conclude that dapagliflozin reduced the risk of adverse kidney outcomes, hospitalisation for HF or cardiovascular death, and prolonged survival in people with CKD, with or without type 2 diabetes, independent of history of HF.
All content for Radcliffe Medical Education is the property of RME Podcast and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this podcast based on the ESC 2021 poster, 'Effects of Dapagliflozin in Patients With Chronic Kidney Disease, With and Without Heart Failure', Prof John McMurray (University of Glasgow, UK) provides a comprehensive overview of the study's background, methods and results.
Previous studies have demonstrated that sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of heart failure (HF) hospitalisation in patients with type 2 diabetes, including in those with chronic kidney disease (CKD). This reduced risk is also evident in patients with HF or CKD with or without type 2 diabetes. In the DAPA CKD study, the authors examined the outcomes in patient with CKD with and without type 2 diabetes by history of HF at baseline.
Here, the poster authors conclude that dapagliflozin reduced the risk of adverse kidney outcomes, hospitalisation for HF or cardiovascular death, and prolonged survival in people with CKD, with or without type 2 diabetes, independent of history of HF.
In this podcast based on the ESC 2021 poster, 'Effects of Dapagliflozin in Patients With Chronic Kidney Disease, With and Without Heart Failure', Prof John McMurray (University of Glasgow, UK) provides a comprehensive overview of the study's background, methods and results.
Previous studies have demonstrated that sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of heart failure (HF) hospitalisation in patients with type 2 diabetes, including in those with chronic kidney disease (CKD). This reduced risk is also evident in patients with HF or CKD with or without type 2 diabetes. In the DAPA CKD study, the authors examined the outcomes in patient with CKD with and without type 2 diabetes by history of HF at baseline.
Here, the poster authors conclude that dapagliflozin reduced the risk of adverse kidney outcomes, hospitalisation for HF or cardiovascular death, and prolonged survival in people with CKD, with or without type 2 diabetes, independent of history of HF.
In this podcast based on the ESC 2021 poster, 'Effects of Dapagliflozin in Patients With Chronic Kidney Disease, With and Without Heart Failure', Prof John McMurray (University of Glasgow, UK) provides a comprehensive overview of the study's background, methods and results.
Previous studies have demonstrated that sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of heart failure (HF) hospitalisation in patients with type 2 diabetes, including in those with chronic kidney disease (CKD). This reduced risk is also evident in patients with HF or CKD with or without type 2 diabetes. In the DAPA CKD study, the authors examined the outcomes in patient with CKD with and without type 2 diabetes by history of HF at baseline.
Here, the poster authors conclude that dapagliflozin reduced the risk of adverse kidney outcomes, hospitalisation for HF or cardiovascular death, and prolonged survival in people with CKD, with or without type 2 diabetes, independent of history of HF.
